Arcutis Biotherapeutics, Inc. (ARQT) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Westlake Village, CA, United States. Der aktuelle CEO ist Todd Franklin Watanabe.
ARQT hat IPO-Datum 2020-01-31, 342 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $3.11B.
Arcutis Biotherapeutics, Inc. is a biopharmaceutical company headquartered in Westlake Village, California, specializing in the development and commercialization of innovative treatments for dermatological diseases. The company's lead product candidate, ARQ-151, is a topical roflumilast cream that has completed Phase III clinical trials for plaque psoriasis and atopic dermatitis. Arcutis is advancing a robust pipeline that includes ARQ-154 for seborrheic dermatitis and scalp psoriasis, ARQ-252, a selective topical Janus kinase type 1 inhibitor for hand eczema and vitiligo, and ARQ-255, a deeper-penetrating topical formulation designed to treat alopecia areata. The company was incorporated in 2016 and rebranded as Arcutis Biotherapeutics in 2019.
